股票
板块
用户
资讯
首页
天眼
自选
发现
开户
首页
天眼
自选
发现
我的

【案例】从复杂工艺到稳定交付:创新药API开发中的工艺破局


一条在实验室中能够完成合成的工艺,并不意味着可以直接用于GMP生产。

随着创新药靶点和分子结构日益复杂,小分子API开发面临的挑战已不只是“能否合成”。物料稳定性不足、工艺重现性较差及关键步骤质量波动,都可能影响工艺放大、验证、CMC申报及后续供应。

如何将实验室工艺转化为稳定、可控、可放大的GMP制造方案,成为复杂小分子API开发的关键挑战。



从物料稳定性入手,寻找工艺问题的根源

一家创新生物医药企业在推进一款肿瘤领域候选药物时,遇到了多项相互关联的工艺挑战。部分物料和关键中间体稳定性不足,原有工艺重现性有待提升,而项目又需在有限时间内推进GMP生产、工艺验证及相关CMC工作,对技术判断、风险识别和项目执行提出了较高要求。

面对这些挑战,客户找到了九洲药业。

九洲药业团队从物料关键质量属性入手,建立分析方法,研究降解行为及影响稳定性的主要因素。在此基础上,团队进一步优化包装、储存和使用条件,将稳定性研究结果转化为具体的物料控制措施。

针对关键步骤中的氧化风险,九洲药业团队通过系统实验识别主要影响因素,并将研究结论落实到关键工艺参数和过程控制措施中,以降低杂质形成和批次质量波动风险。

通过持续优化反应条件、后处理方式及关键操作,项目的工艺稳定性、重现性和整体效率得到改善,为后续GMP生产、工艺验证及规模化供应奠定了基础。


从解决单点问题,到建立系统控制策略

复杂API项目中的稳定性和杂质问题,通常不是由单一因素造成。物料性质、储存条件、反应时间、温度、溶剂体系、氧气接触及后处理操作,都可能影响产品质量。如果只依赖终产品检测,而未理解问题发生的原因,相同风险仍可能在放大阶段再次出现。

九洲药业团队将分析研究与工艺开发相结合,通过稳定性数据、杂质趋势和工艺实验,识别关键影响因素并建立控制策略。

有效的工艺优化不只是提高收率,更要理解物料降解、杂质形成及影响产品质量的关键参数。

将这些认识转化为明确、可执行、可验证的控制措施,才能支持后续放大、GMP生产和商业化供应。


让工艺研究真正落到GMP生产中

随着项目进入后期阶段,工艺、分析、生产、质量、验证及注册支持之间的衔接尤为关键。

九洲药业将分析、生产和质量要求提前纳入工艺开发,并结合实际设备、放大条件和GMP要求评估实验室方案。生产与质量数据持续反馈至工艺优化,以进一步明确关键参数和控制要求。

通过各环节紧密配合,工艺研究成果能够更顺利地转化为GMP生产操作,减少技术转移过程中的重复沟通和信息损失。

工艺验证前,团队系统梳理关键物料、工艺参数、过程检测及潜在风险,并制定应对方案;验证生产过程中,通过持续监测和严格控制,进一步确认工艺的稳定性与可执行性。

最终,九洲药业支持项目完成临床阶段API CMC开发、GMP生产、工艺验证及注册申报,并助力客户创新药获得美国FDA批准上市。


客户认可,来自关键阶段的可靠交付

对客户而言,可靠的API合作伙伴不仅要按时交付,更要提前识别风险,在质量、进度、效率和持续供应之间取得平衡。

项目推进过程中,客户多次通过邮件肯定九洲药业团队的投入及交付质量:


“我认为,没有其他CDMO企业能够在如此有限的时间内,以如此高的质量完成这项工作。”

在项目取得重要临床里程碑后,客户再次表示:


“九洲药业在此次成功中发挥了关键作用。正是九洲药业团队在极短时间内坚持高质量标准完成生产,才促成了这一成果。”

客户的认可,既来自关键节点的可靠交付,也来自九洲药业团队对复杂工艺问题的持续研究与快速响应。


从项目成果到持续商业化交付

该项目是2026年以来九洲药业支持的第2个获美国FDA NDA批准的创新药项目。同年,九洲药业还支持5个创新药项目通过批准前检查(PAI)。

这些成果体现了九洲药业将复杂工艺问题转化为稳定制造方案的能力。

未来,九洲药业将继续依托工艺、分析、生产、质量及项目管理能力,为复杂小分子项目提供从API工艺开发、GMP生产到注册支持和商业化供应的全生命周期CDMO服务。



From Complex Processes to Reliable Delivery: Solving API Development and Manufacturing Challenges for Innovative Medicines


A process that works in the laboratory is not necessarily ready for GMP manufacturing.

As drug targets and molecular structures become increasingly complex, small molecule API development may involve limited stability of starting materials and key intermediates, inconsistent process reproducibility, impurity risks, and variability in critical manufacturing steps.

If these issues are not addressed early, they may affect process scale-up, validation, CMC documentation, regulatory submission, and commercial supply readiness.

The challenge is to translate laboratory process knowledge into a robust, controllable, and scalable API manufacturing process suitable for GMP production.



Starting with Material Stability to Identify the Root Cause

An innovative biopharmaceutical company encountered several interconnected process challenges while advancing an oncology candidate.

Certain materials and key intermediates required improved stability, while the existing process needed greater reproducibility and consistency. Process development, GMP manufacturing, process validation, and API-related CMC activities also had to progress within a demanding timeline.

To support the program’s advancement into late-stage development, the customer selected JiuZhou Pharma as its API development and manufacturing partner.

The JiuZhou Pharma team began by studying the critical quality attributes of the relevant materials. Analytical methods were established and strengthened to evaluate degradation behavior and identify the main factors affecting stability.

Based on these findings, packaging, storage, and handling conditions were optimized, translating stability data into practical material control measures.

For a critical process step involving oxidation risk, the team systematically evaluated potential contributing factors and converted the findings into defined critical process parameters and in-process controls. These measures helped reduce impurity formation and batch-to-batch variability.

Continued optimization of reaction conditions, work-up procedures, and critical operations improved process robustness, reproducibility, and overall efficiency, establishing a stronger foundation for GMP manufacturing, process validation, and future scale-up.


From Solving Individual Issues to Building a Systematic Control Strategy

Stability and impurity issues in complex API programs are rarely caused by a single factor. Material properties, storage conditions, reaction time, temperature, solvent systems, oxygen exposure, and work-up operations may all affect product quality.

When a process relies only on final product testing without understanding when and why an issue occurs, the same risk may reappear during scale-up.

In this project, JiuZhou Pharma combined analytical development with process development to assess stability data, impurity trends, and experimental results. This allowed the team to identify critical factors and establish a science-based process control strategy.

Effective API process optimization goes beyond improving the yield of an individual reaction. It requires a clear understanding of material degradation, impurity formation, critical process parameters, scale-up behavior, and GMP operability.

The objective is to convert process understanding into practical, monitorable, and verifiable controls that can support process scale-up, GMP manufacturing, and commercial supply.


Translating Process Development into GMP Manufacturing

As the program advanced, close alignment across process development, analytical development, GMP manufacturing, quality management, process validation, and regulatory support became increasingly important.

JiuZhou Pharma incorporated analytical, manufacturing, and quality requirements early in process development. Laboratory solutions were evaluated against actual equipment, scale-up conditions, and GMP operating requirements, helping translate process knowledge into executable manufacturing procedures.

Manufacturing and quality data were then fed back into ongoing process optimization, supporting further definition of critical process parameters and control requirements.

Before process validation, the team systematically reviewed critical materials, process parameters, in-process controls, and potential operating risks. During validation manufacturing, continued monitoring and disciplined process control helped confirm process robustness and operational feasibility.

JiuZhou Pharma supported the program from clinical-stage API CMC development and GMP manufacturing through process validation and regulatory submission, contributing to the customer’s U.S. FDA approval milestone.


Customer Recognition Built on Reliable Delivery

For innovative drug companies, the value of an API partner extends beyond completing a specific manufacturing campaign. Customers need a partner that can identify technical risks early and balance quality, timelines, manufacturing efficiency, and long-term supply requirements.

Throughout the collaboration, the customer recognized the JiuZhou Pharma team’s commitment and quality of delivery:


“I don’t think any other CDMO could have pulled this off in the limited timeframe and at such a high level of quality.”

Following an important clinical milestone, the customer further noted:


“JiuZhou Pharma played a key role in this success. The team’s ability to manufacture to high quality standards within a very short timeframe made this achievement possible.”

The customer’s recognition reflected both reliable delivery at critical milestones and the JiuZhou Pharma team’s continued technical investigation and responsiveness throughout the program.


From Program Milestones to Commercial Supply

This program represents the second JiuZhou Pharma-supported innovative drug NDA to receive U.S. FDA approval in 2026. In addition, JiuZhou Pharma has supported five innovative drug programs through successful Pre-Approval Inspections in 2026.

From material stability studies, oxidation risk management, and impurity control to API process development, GMP manufacturing, process validation, and regulatory submission support, the program demonstrates JiuZhou Pharma’s ability to translate complex technical challenges into robust manufacturing solutions.

JiuZhou Pharma will continue to provide lifecycle CDMO services spanning API process development, GMP manufacturing, regulatory support, and commercial supply for complex small molecule and peptide programs.

原文链接
多空观点 观点仅供交流,不构成投资建议
点赞
踩一踩
收藏
分享

评论 (0)

0/200
声明:社区内容仅代表用户个人观点,不构成任何投资建议。投资有风险,入市需谨慎。